Why the study?
Are differences in blood pressure, LDL-C, and other risk factors associated with the progression of angiographic coronary artery disease?
Observational (n=183)
No
Are differences in blood pressure, LDL-C, and other risk factors associated with the progression of angiographic coronary artery disease?
Absolute Event Rate: 97% vs 92%
p-value: p=0.01
Higher mean arterial pressure and diastolic blood pressure are associated with angiographic progression of coronary artery disease, highlighting the importance of strict blood pressure control.
Mean arterial pressure elevation was associated with angiographic CAD progression; leaves open whether BP lowering alters outcomes in prospective trials.
Introduction: To investigate differences between outpatients with progressive and nonprogressive coronary artery disease (CAD) measured by coronary angiography. Material and methods: Chart reviews were performed in patients in an outpatient cardiology practice having 2 coronary angiographies 1 year apart. Progressive CAD was defined as 1) new non-obstructive or obstructive CAD in a previously disease-free vessel; or 2) new obstruction in a previously non-obstructive vessel. Coronary risk factors, comorbidities, cardiovascular events, medication use, serum low-density lipoprotein cholesterol (LDL-C), and blood pressure were used for analysis. Results: The study included 183 patients, mean age 71 years. Mean follow-up duration was 11 years. Mean follow-up between coronary angiographies was 58 months. Of 183 patients, 108 (59%) had progressive CAD, and 75 (41%) had nonprogressive CAD. The use of statins, -blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and aspirin was not significantly different in patient with progressive CAD or nonprogressive CAD Mean arterial pressure was higher in patients with progressive CAD than in patients with nonprogressive CAD (97 13 mm Hg vs. 92 12 mm Hg) (p < 0.05). Serum LDL-C was insignificantly higher in patients with progressive CAD (94 40 mg/dl) than in patients with nonprogressive CAD (81 34 mg/dl) (p = 0.09). Conclusions: Our data suggest that in addition to using appropriate medical therapy, control of blood pressure and serum LDL-C level may reduce progression of CAD.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2012) conducted an observational in Coronary artery disease (n=183). Progressive CAD vs. Nonprogressive CAD was evaluated on Mean arterial blood pressure (mm Hg) (p=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: